How to securely transfer real-time data to cloud-based platforms without extra burden to your existing data systems?

DOWNLOAD WHITEPAPER

ODIN empowers the connectivity of real-time data with cloud-based systems, machine learning and AI platforms in an easy, secure, and cost-effective way. ODIN securely transfers real-time data to cloud-based platforms, including Amazon S3, Microsoft Azure, IOT Hubs, SQL Server and more, without extra burden to your existing data systems. Compatible with both OSIsoft PI & Wonderware historians, ODIN aggregates, filters, contextualizes, and delivers formatted data securely & efficiently via a web-based dashboard. ODIN also has in-built audit trails and the web-based configuration that allows easy data egress and ingress.

ODIN provides an easy-to-use tool to solve the need for automated data extracts and remove the time-consuming process of extracting and contextualizing data. This allows valuable time to be refocused back to data science and empower analytics. With ODIN, companies can make key business decisions and operational improvements through the utilization of existing data, bringing Industry 4.0 and digital strategies to the next level. As the industry leader in data intelligence, we are committed to help our customers in Pharmaceutical and Life Sciences achieve process manufacturing advances and propel towards Industry 4.0.

sales@tqsintegration.com

www.tqsintegration.com

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: MyonexGo to article: Controlant Company InsightGo to article: ControlantGo to article: SHL MedicalGo to article: LabcorpGo to article: ReutersGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: TQS Integration Company InsightGo to article: TQS IntergrationGo to article: Biesterfeld Go to article: CommentGo to article: Biotech and China: a global opportunityGo to article: Intranasal ketamine could effectively treat phantom painGo to article: EU biosimilar wave slows as biosimilar approvals decrease in the EUGo to article: Biosynth Carbosynth Company InsightGo to article: Biosynth CarbosynthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: SkyepharmaGo to article: In DepthGo to article: Unpacking the complex challenge of biologicsGo to article: Living medicines: using bacteria to fight cancerGo to article: The marred history of HIV vaccine trialsGo to article: Has Covid-19 exposed the weakness of the US pharma supply chain?Go to article: How the pandemic pushed pharmacovigilance to innovateGo to article: ExeVir: the llama-derived antibody that could fight Covid-19Go to article: BEA TechnologiesGo to article: WatlowGo to article: DuojectGo to article: ButterworthGo to article: In DataGo to article: Data: Big Data hiring efforts in pharmaGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue